Recent trials have shown survival benefits of intensified regimens in EGFR-mutant NSCLC, but they come at the cost of increased toxicity and treatment burden. So which patients should receive up-front intensification?
Join our experts for a discussion- and case-based webinar exploring the latest in NTRK fusion-positive non-small-cell lung cancer and equip yourself to best manage this subset of patients.
The treatment strategy for liver metastases is predominantly determined by the primary cancer site, which made this patient with metastases from breast and colorectal cancer quite challenging to manage.
CAR T-cell therapy for central nervous system tumors in children and adults induces unique neurotoxicities. Learn about the underlying mechanisms, clinical implications, and management approaches.
Marking a major milestone in chronic myeloid leukemia treatment
Tyrosine kinase inhibitors have transformed the treatment of chronic myeloid leukemia, a condition that had limited therapeutic options before.
In this 25th year since the first phase 2 trials of the first TKI, we speak to a researcher and clinician who has been involved since the early days. Dr. Jorge Cortes shares his experience and talks about the impact of these drugs, not only in the treatment of CML but also more widely.
Are you up to date on targeted therapies for relapsed/refractory AML?
Join Prof. Amer Zeidan and his expert guests to hear about innovations in molecular testing, emerging therapies, and IDH-targeted treatments, and get practical advice for improving your patient care.
Supported by: independent educational grant from Rigel
Join Professor Joy Ho as she leads a panel of Asia-Pacific-based experts, discussing real-life patient cases and their experiences with CAR T-cell therapy for the treatment of R/R DLBCL or R/R FL. Learn about how to identify appropriate patients for CAR T-cell therapy and how to optimize outcomes with this treatment modality. Gain insights into essential aspects of pre- and post-infusion management, as well as important considerations for treatment sequencing.
This educational activity is not intended for healthcare professionals based in the UK, US, or off-label Asia-Pacific countries.
The treatment strategy for liver metastases is predominantly determined by the primary cancer site, which made this patient with metastases from breast and colorectal cancer quite challenging to manage.
Carfilzomib is mostly associated with gastrointestinal or cardiovascular side effects, but this patient with relapsed multiple myeloma developed pulmonary complications, which resolved once the drug was discontinued.
Bilateral IPE cysts in a 3-year-old triggered investigations that revealed acute lymphoblastic leukemia. Chemotherapy reduced the cysts, supporting a possible link between IPE cysts and hematologic malignancies.
Neoadjuvant therapy (NAT) for early breast cancer was first introduced in the 1980s to downstage large, inoperable tumors, and thereby enable less extensive surgical resections. Beyond its surgical benefits, NAT offers the unique advantage of …
Triple-negative breast cancer (TNBC) is best characterized by high aggressiveness and significant biological heterogeneity. Although the current TNBC clinical trials include genomic biomarkers to stratify treatment arms, they are still limited by …
Hepatocellular carcinoma (HCC) remains one of the most lethal malignancies worldwide, with its pathogenesis involving complex biological processes such as DNA damage, epigenetic modification and oncogene mutation. Over the past two decades, the …
Congenital portosystemic shunts are rare and have high association with the development of focal liver lesions. Distinguishing between benign and malignant hepatic tumors in these patients can be difficult, both via imaging and histopathology.
Professor Joy Ho and a panel of Asia-Pacific-based experts will examine real-life patient cases in this Masterclass, exchanging insights into their clinical experiences of using CAR T-cell therapy to treat patients with R/R DLBCL or R/R FL.
This educational activity is not intended for healthcare professionals based in the UK, US, or off-label Asia-Pacific countries.
This hub presents a curated selection of educational materials focused on the latest clinically relevant topics related to the use of chimeric antigen receptor (CAR) T‑cell therapy for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and R/R follicular lymphoma (FL).
This content has been developed in collaboration with and funded by the sponsor Novartis Pharma AG and is not intended for healthcare professionals based in the UK and US.
Hear directly from experts in acute myeloid leukemia about innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.
Growing teratoma syndrome (GTS) is a rare clinical condition occurring in women with malignant ovarian germ cell tumors, with paradoxical findings of normal serum tumor markers and enlarging metastatic lesions during the adjuvant chemotherapy …
Gastric cancer is a prevalent malignancy on a global scale and ranks as the fourth leading cause of mortality worldwide [ 1 ]. Over the decades, the pattern of GC in both of Western and Asian countries has changed, with an ascending proportion of …
Diffusion-weighted imaging (DWI) visualizes tissue characteristics by measuring the random motion of water molecules, thereby providing valuable information about the tissue microenvironment, such as tissue cellularity and cell membrane integrity …
Breast cancer represents a significant public health concern worldwide [ 1 ]. In Italy, according to the Italian Association of Cancer Registries, approximately 55,900 new cases were diagnosed in 2023, with a five-year survival rate of 88% and an …
Carfilzomib is mostly associated with gastrointestinal or cardiovascular side effects, but this patient with relapsed multiple myeloma developed pulmonary complications, which resolved once the drug was discontinued.
Recent trials have shown survival benefits of intensified regimens in EGFR-mutant NSCLC, but they come at the cost of increased toxicity and treatment burden. So which patients should receive up-front intensification?
